EBV-associated lymphoproliferative disorder (LPD) is a rare but serious complication in marrow transplant recipients. A 31-year-old Japanese woman in the second chronic phase of CML received an allogeneic BMT from her HLA 2-locus-incompatible 62-year-old father. Around day +200, she developed EBV-LPD of the right parieto-temporal lobe which caused slowly progressive left hemiparesis. Two courses of donor lymphocyte transfusions (DLT) of 10 6 CD3 + T cells/kg of body weight failed to suppress her central nervous system (CNS) EBV-LPD. The patient died of recurrent blastic crisis of CML. This case suggests that DLT may be ineffective for the treatment of CNS EBV-LPD. Keywords: Epstein-Barr virus-associated lymphoproliferative disorder; donor lymphocyte transfusion; central nervous system EBV-associated lymphoproliferative disorder (LPD) is a rare but serious complication in marrow transplant recipients.
EBV-associated lymphoproliferative disorder (LPD) is a rare but serious complication in marrow transplant recipients. 1, 2 Although there are reports of successful treatment of polyclonal or oligoclonal proliferations with agents such as interferon-␣ and intravenous ␥-globulin, high-dose acyclovir, and anti-B-cell MoAb, [3] [4] [5] monoclonal disease has remained refractory to treatment in marrow transplant recipients.
Recently, donor lymphocyte transfusions (DLT) have been shown to be an effective treatment for EBV-LPD. 6, 7 We report the case of a Japanese woman, who developed EBV-LPD of the right cerebrum following allogeneic BMT and who was then treated with DLT.
Case report
A 31 year-old Japanese woman was admitted to our hospital for the treatment of myeloid blastic crisis (BC) of CML Correspondence: Dr K Nagafuji, Department of Hematology, Hara Sanshin General Hospital, 1-8 Taihaku-machi, Hakata-ku, Fukuoka 812, Japan Received 4 August 1997; accepted 22 December 1997 in July 1996. She entered the second chronic phase after treatment with vincristine and prednisolone. The patient had no HLA-identical siblings, nor were there any HLAidentical unrelated donors in the Japan Marrow Donor Program. Because of the poor prognosis in BC, we decided to perform a BMT using her HLA 2-locus-incompatible 62-year-old father as donor. The donor was seropositive for human T cell leukemia virus type 1 (HTLV-1), while the recepient was seronegative. 8 Both the recipient and the donor were seropositive for EBV (VCA IgG ×40 VCA IgM Ͻ×10 EBNA ×10, VBCA IgG ×640 VCA IgM Ͻ×10 EBNA ×10, respectively).
The pre-transplant conditioning consisted of BU 4 mg/kg orally in divided doses daily on days −8 to −5, and CY 50 mg/kg i.v. daily on days −4 to −2. Because of ABO major incompatibility, bone marrow mononuclear cells isolated by density-gradient centrifugation (1.8 × 10 8 /kg of body weight) were given. Tacrolimus (FK506; Fujisawa, Osaka, Japan) in combination with MTX was used for GVHD prophylaxis. Grade II GVHD of the skin developed on day +11 but this responded well to high-dose methylprednisolone therapy. Granulocytes exceeded 0.5 × 10 9 /l on day +16, and platelets exceeded 50 × 10 9 /l on day +26. Prolonged administration of immunosuppressive agents was required for control of GVHD. Complications following BMT included CMV-associated disease and two episodes of herpes zoster. Around day +200, she developed lowgrade fever and slowly progressive left hemiparesis. Contrast-enhanced T 1 -weighted magnetic resonance imaging (MRI) of the brain on day +214 revealed a ring-enhanced hypo-intensity lesion of the right parieto-temporal lobe (Figure 1a) . On day +218, histologic sections of the stereotactic biopsy showed a diffuse polymorphic medium-tolarge cell lymphoid cell proliferation with extensive areas of necrosis. Immunohistochemical studies performed on paraffin-embedded sections demonstrated that lymphoid cells were positive for CD20, but negative for CD3. Lymphoid cells were also positive for LMP-1 and EBNA-2. In situ hybridization studies demonstrated the presence of EBV-RNA in the nuclei of many lymphoid cells (Figure 2) . 9 EBV-LPD was diagnosed. Administration of immunosuppressive agents was then discontinued. On day +218, EBV DNA within peripheral blood nucleated cells (PBNC) was detected by PCR ( Figure 3) . 10 On day +226, she received 10 6 CD3 + T cells/kg of body weight from her donor. Fourteen days after the first DLT, EBV DNA within PBNC could no longer be detected by PCR. However, her neurological symptoms did not improve, and MRI on day +246 showed slight enlargement of the right parieto-temporal lesion (Figure 1b) . On day +247, a second DLT of 10 6 CD3 + T cells/kg was given, but this also produced no neurological improvement. There was no exacerbation of GVHD by DLT.
Myeloid BC of CML recurred on day +249. She died of CML progression on day +263. An autopsy was performed. The right parieto-temporal lesion showed viable atypical lymphoid cells with massive necrosis. There was no evidence of EBV-LPD other than in the central nervous system (CNS).
Discussion
Risk factors for post-transplant EBV-LPD have been reported to be the severity of acute GVHD, HLA disparity between marrow donor and recipient, treatment of acute GVHD using CD3 MoAb, and T cell depletion of the marrow graft.
1,2 Our patient received a non-T-cell-depleted BMT from her HLA 2-locus-incompatible 62-year-old father and developed grade II acute GVHD and extensive chronic GVHD requiring prolonged administration of FK506 and steroids. Furthermore, her donor was seropositive for HTLV-1, which may have exacerbated her posttransplant immunosuppressed state. 8 With the first DLT, EBV in the peripheral blood was eradicated rapidly judging from the results of PCR analysis. Nevertheless, the lesion within the CNS did not regress. Anti-B cell MoAb have been reported to be effective in controlling EBV-LPD when the CNS is not involved. 3 The reason why anti-B cell MoAb were not effective against CNS EB-LPD remains to be elucidated, but the suggestion is that penetration of MoAb into the CNS might be poor.
DLT for the treatment of EB-LPD has been reported to be effective although it is sometimes associated with exacerbation of GVHD. 6, 7 To the best of our knowledge, this is the first report of DLT for the treatment of EB-LPD in the CNS. It was not clear whether the infused lymphocytes had penetrated into the CNS. The observation period might not be sufficiently long to determine the effect of DLT, since our patient died of recurrent BC of CML after 37 days from the first DLT.
However, considering the fact that DLT eradicated EBV in the peripheral blood but failed to suppress CNS EBV-LPD in our patient, DLT may not be effective for the treatment of CNS EBV-LPD as is the case after anti-B-cell MoAb treatment. 
